Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride

British Journal of Ophthalmology

Volumn 92, Issue 9, 2008, Pages 1275-1282

  Liang, H ^a,b   Baudouin, C ^b,c,d   Pauly, A ^a,b   Brignole Baudouin, F ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; CD45 ANTIGEN; LATANOPROST; PHOSPHATE BUFFERED SALINE; TAFLUPROST; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DRUG EXPOSURE; EYE TOXICITY; FLOW CYTOMETRY; IMMUNOHISTOLOGY; IMPRESSION CYTOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLIT LAMP;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; COLORING AGENTS; CONJUNCTIVA; CORNEA; EPITHELIAL CELLS; IMMUNOHISTOCHEMISTRY; KERATOCONJUNCTIVITIS; MALE; OPHTHALMIC SOLUTIONS; OXAZINES; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; RABBITS;

EID: 51149102297     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2008.138768     Document Type: Article

References (31)

1. Ishida N, Odani-Kawabata N, Shimazaki A, et al. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 2006;24:1-10.
2. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypertensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-15.
3. Ota T, Murata H, Sugimoto E, et al. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci 2005;46:2006-11.
4. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-15.
5. Guenoun JM, Baudouin C. Rat P, et al. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:4594-9.
6. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-50.
7. Rolando M, Brezzo G, Giordano P, et al. The effect of different benzalkonium chloride concentrations on human normal ocular surface: a controlled prospective impression cytology study. In: Van Bijsterveld OP, Lemp MA, Spinelli D, eds. The lacrimal system. Amsterdam: Kugler, 1991:89-91.
8. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-30.
9. Debbasch C, Pisella PJ, De Saint Jean M, et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:2525-33.
10. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339-43.
11. Baudouin C, Riancho L, Warnet JM, et al. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123-8.
12. Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharma Bull 2003;26:1691-5.
13. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 2004;78:767-76.
14. Ota T, Aihara M, Saeki T, et al. The lOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol 2007;91:673-6.
15. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, bimatoprost in a conjunctival epithelial cell line. Curr Eye Res 2008;33:303-12.
16. Liang H, Baudouin C, Labbe A, et al. In vivo confocal microscopy and ex vivo flow cytometry: new tools for assessing ocular inflammation applied to rabbit lipopolysaccharide-induced conjunctivitis. Mol Vis 2006;12:1392-402.
17. Liang H, Brignole-Baudouin F, Labbe A, et al. LPS-stimulated inflammation and apoptosis in corneal injury models. Mol Vis 2007;13:1169-80.
18. Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 2008;14:204-16.
19. Labbe A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006;22:267-78.
20. Pauly A, Brignole-Baudouin F, Labbe A, et al. New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci 2007;48:5473-83.
21. Ichijima H, Petroll WM, Jester JV, et al. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992;11:221-5.
22. Labbe A, Liang H, Martin C, et al. Comparative anatomy of laboratory animal corneas with a new-generation high-resolution in vivo confocal microscope. Curr Eye Res 2006;31:501-9.
23. Nelson JD. Impression cytology. Cornea 1988;7:71-81.
24. Wilson WS, Duncan AJ, Jay JL Effect of benzalkonium chloride on the stability of the precomeal tear film in rabbit and man. Br J Ophthalmol 1975;59:667-9.
25. Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol 1995; 79:339-42.
26. Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994;101:454-60.
27. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-63.
28. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Opthalmol 1994;232:561-5.
29. Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Opthalmol 2003;241:1037-43.
30. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8.
31. Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy mates. J Ocul Pharmacol Ther 2007;23:359- 65.